Literature DB >> 6538328

Criteria for the establishment of a double-labeling assay for simultaneous determination of estrogen and progesterone receptors.

H J Grill, B Manz, O Belovsky, K Pollow.   

Abstract

The availability of [125I]-16 alpha-iodo-3,17 beta-estradiol ( [125I]-E2) with binding characteristics similar to estrogen receptor (ER) enabled us to establish a double-labeling assay for the simultaneous determination of ER and progesterone receptors (PgR) using 125I-E2 and [3H]-R5020. The criteria for the establishment of such a double-labeling assay are described. 150 human mammary tumor cytosols have been investigated with the standard routine receptor assay for ER as well as PgR and the results were compared to those obtained by the double-labeling assay. ER: a coefficient of correlation of 0.691 was obtained, the parameters of the regression line were Y = 1.025 X X-0.036. When referring to the standard assay, 3 determinations were false-positive and 4 false-negative. PgR: a correlation coefficient of 0.984 was found, the parameters of the regression line were Y = 0.960 X X + 12.16. One value was false-negative and 1 false-positive. An equivalence of the two methods could be demonstrated. This new assay reduces by half the amount of tissue necessary for a valid 4- to 6-point saturation analysis, the time required for performing the assay and its cost.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6538328     DOI: 10.1159/000225785

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  3 in total

1.  Androgen receptors, serum androgen levels and survival of breast cancer patients.

Authors:  M Langer; E Kubista; M Schemper; J Spona
Journal:  Arch Gynecol Obstet       Date:  1990       Impact factor: 2.344

2.  The tumour-inhibiting potential of the progesterone antagonist Onapristone in the human mammary carcinoma T61 in nude mice.

Authors:  M R Schneider; H Michna; U F Habenicht; Y Nishino; H J Grill; K Pollow
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

3.  First experience with FGF-3 (INT-2) amplification in women with epithelial ovarian cancer.

Authors:  A Rosen; P Sevelda; M Klein; K Dobianer; C Hruza; K Czerwenka; H Hanak; N Vavra; H Salzer; S Leodolter
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.